Skip to main content
Fig. 3 | BMC Medical Genetics

Fig. 3

From: A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients – Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC)

Fig. 3

LoD for the Mutation assay. DNA from FGFR3 mutant plasmids was diluted into the wild-type DNA (standard human DNA). The proportion of mutant DNA was 50, 10, 5, and 1%, respectively. The representative amplification curves (a, c) and mean Ct values (b, d) are shown in the detection of the FGFR3 S249C/Y375C (a, b) and R248C/G372C (c, d) mutations by MASO-PCR

Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us